AMD3100, the only marketed CXCR4 antagonist approved to mobilize hematopoietic stem cells in cancer patients62 and currently also in advanced clinical trials for therapy of other CXCR4-associated diseases, showed a high nanomolar Ki with 221 nM. Here, CXCR4 is linked to cancer.